Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New oncolytic agents and immunomodulators and their application].

N H Mulder1

  • 1Universitair Medisch Centrum Groningen, afd. Medische Oncologie, Postbus 30.001, 9700 RB Groningen.

Nederlands Tijdschrift Voor Geneeskunde
|July 14, 2005
PubMed
Summary

Recent advances in colorectal cancer treatment, including new drugs like oxaliplatin and bevacizumab, have significantly improved patient survival. These systemic therapies and surgical options offer new hope for metastatic disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival of non-Western first generations immigrants with stomach cancer in North East Netherlands.

British journal of cancer·2011
Same author

FDG-PET probe-guided surgery for recurrent retroperitoneal testicular tumor recurrences.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2010
Same author

Effect of hospital characteristics on outcome of patients with gastric cancer: a population based study in North-East Netherlands.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2010
Same author

Skin capillary permeability in the diabetic foot with critical limb ischaemia: the effects of a phVEGF165 gene product.

Diabetic medicine : a journal of the British Diabetic Association·2008
Same author

Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients.

Bone marrow transplantation·2008
Same author

Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial.

Human gene therapy·2006

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • Colorectal cancer treatment has seen recent significant advancements after a prolonged period of stagnation.
  • Improved diagnostic methods now allow for earlier detection of metastatic disease, including liver metastases, enabling curative surgical interventions.

Purpose of the Study:

  • To summarize recent progress in colorectal cancer treatment and research.
  • To highlight the impact of new systemic therapies and surgical options on patient survival.

Main Methods:

  • Review of recent developments in colorectal oncology, focusing on systemic treatments and surgical approaches.
  • Analysis of the efficacy of cytotoxic drugs (oxaliplatin, irinotecan) and targeted therapies (bevacizumab) in metastatic colorectal cancer.

Related Experiment Videos

Main Results:

  • Patient survival for metastatic colorectal cancer has increased to a median of approximately 18 months due to earlier systemic treatment and new drugs.
  • Oxaliplatin and irinotecan have contributed to improved outcomes.
  • Addition of bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor) demonstrated survival benefits comparable to cytotoxic agents.
  • Oxaliplatin is also effective in the adjuvant setting post-surgery for primary colon cancer.

Conclusions:

  • Recent therapeutic strategies have markedly improved survival rates in colorectal cancer patients with metastatic disease.
  • The combination of novel drugs and surgical interventions represents a significant step forward in managing colorectal cancer.
  • While treatment costs are considerable, their impact on the overall drug economy is relatively small.